Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Pushes for Patient Interests, Against Spending Cuts

Angus Worthing, MD, FACP, FACR  |  July 5, 2017

Greetings from Washington, D.C. Your advocacy team had another busy month. Unlike my prior updates, and in order to keep our focus on health policy, I avoid mentioning anything about Washington investigations into obstruction of justice, collusion, etc. You get enough of that elsewhere.

The Healthcare Bill
Obamacare repeal and reform efforts are speeding up. As many of you know, the House passed a bill repealing and replacing components of Obamacare (see my #simpletasks update here). The Senate did not hold public hearings on its version of the healthcare bill, but like the House, wrote the bill in secret, as The New York Times reported. The ACR notified Senate leadership through letters and more than 100 in-person meetings in May about how best to protect the interests of our patients and our profession. We’re currently following up on those contacts.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Meanwhile, everyone reading this can easily send a prewritten, editable letter to their senators by visiting the ACR’s Legislative Action Center and clicking on “take action.” It takes just a minute—and now is the perfect time. Your leaders need to hear your voice.

Trump’s Skinny Budget for FY18
The ACR joined with many health advocates in opposing the Trump administration’s proposals for sweeping cuts to NIH, Medicaid, CHIP and taxpayer funding of FDA. Of note, budget proposals are just that—proposals—and Congress ultimately decides the federal budget. Thankfully, many members of Congress oppose Trump’s cuts. But Trump has created a tone of spending cuts. Meanwhile, the ACR does endorse two rheumatology-friendly parts of the budget, those that would boost funding for graduate medical education and repeal IPAB, the Medicare-cutting mechanism.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As Congress begins the budget process, your advocacy team has also established strong support for a new, dedicated arthritis funding stream through the Department of Defense (DoD). Take a minute to send an email to your member of Congress asking them to repeal IPAB and support arthritis research (go here and click on “7 advocacy campaigns” or Google “rheumatology legislative action center”).

ACR Helps Reduce Administrative Burdens
The ACR recently met with leaders of Health and Human Services (HHS) and also sent a letter to CMS Administrator Seema Verma, requesting regulatory relief to reduce administrative burdens. We advocated for modifying billing codes to reflect the value of rheumatology care, improving transparency in the way the CMS makes rules and making both tracks of MACRA (MIPS and APMs) more feasible for rheumatologists. Read the letter here.

Page: 1 2 3 | Single Page
Share: 

Filed under:EULAR/OtherFrom the CollegeLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR advocacyAlliance for Transparent & Affordable Prescriptions (ATAP)alternative payment models (APMs)BiosimilarsEULARMedPacMIPSObamacare repealpharmacy benefit managers (PBMs)Washington D.C. update

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Speak Up: Ask Congress to Block Medicare Reimbursement Cuts

    October 22, 2021

    Rheumatologists may need to downsize and restrict patient care if Congress doesn’t act to block significant cuts to Medicare reimbursement rates totaling 9.75% in 2022.

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences